Longeveron (NASDAQ:LGVN) Stock Price Down 3.2% – What’s Next?

Shares of Longeveron Inc. (NASDAQ:LGVN) fell 3.2% on Monday . The company traded as low as $0.5349 and last traded at $0.5404. 525,094 shares changed hands during trading, an increase of 18% from the average session volume of 444,404 shares. The stock had previously closed at $0.5580.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Longeveron in a report on Wednesday, October 8th. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $6.50.

Longeveron Trading Down 3.2%

The firm has a 50 day moving average of $0.70 and a 200-day moving average of $0.96. The company has a market cap of $11.53 million, a P/E ratio of -0.51 and a beta of 0.19.

Longeveron (NASDAQ:LGVN) last announced its quarterly earnings data on Tuesday, November 4th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.13). The company had revenue of $0.14 million for the quarter, compared to analysts’ expectations of $0.29 million. Longeveron had a negative net margin of 1,485.25% and a negative return on equity of 138.44%. Equities analysts predict that Longeveron Inc. will post -3.69 EPS for the current fiscal year.

Institutional Trading of Longeveron

An institutional investor recently bought a new position in Longeveron stock. XTX Topco Ltd acquired a new stake in shares of Longeveron Inc. (NASDAQ:LGVN) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 48,003 shares of the company’s stock, valued at approximately $62,000. XTX Topco Ltd owned approximately 0.32% of Longeveron as of its most recent SEC filing. Institutional investors own 10.01% of the company’s stock.

Longeveron Company Profile

Longeveron Inc is a clinical-stage biotechnology company focused on the development and commercialization of allogeneic cellular therapies designed to address aging-related and inflammatory conditions. The company’s primary therapeutic candidate, Lomecel-B, is an off-the-shelf mesenchymal stem cell product derived from bone marrow. Through its proprietary manufacturing process, Longeveron aims to produce a consistent, scalable cell therapy platform with potential applications in multiple disease areas.

Longeveron’s pipeline encompasses several ongoing and completed clinical studies.